All Stories

Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations.

Feb 13, 2025 - 14:19
 0
Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials
Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations.
Read More

Tags:

Previous Article

How America became so car dependent

Next Article

Activist hedge fund reportedly amasses £3.8bn stake in BP

Related Posts

New AI-discovered protein compounds kill bacteria and fungi infecting mice: study

New AI-discovered protein compounds kill bacteria and f...

Feb 9, 2025  0

Theriva puts GvHD drug on backburner to focus on oncolytic adenovirus

Theriva puts GvHD drug on backburner to focus on oncoly...

Mar 7, 2025  0

Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery

Aldeyra’s dry eye drug suffers second FDA rejection, bu...

Apr 3, 2025  0